Clinical Trial Update: To Demonstrate the Relative Bioequivalency Study of Dosage Forms of Clemastine 2.68 mg Tablets [Phase 1]

View source ↗

Summary

Phase 1 study completed to demonstrate the relative bioequivalence of two dosage forms of clemastine 2.68 mg tablets in individuals with allergy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergy

Drugs mentioned

• Clemastine (clemastine)

Snippet

Sponsor: Sandoz | Conditions: Allergy | Phase 1 | Status: COMPLETED